Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr

How Risk Stratification Might Affect Women’s Health

Various factors should be considered when planning to screen for breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

When planning a screening program to detect the early signs of breast cancer, age is a major consideration. But it should not be the only one, said Diana Miglioretti, Ph.D., a biostatistics professor at the University of California, Davis.

In an April 5 presentation at the Society for Breast Imaging (SBI)/American College of Radiology (ACR) Breast Imaging Symposium in Hollywood, Fla., Miglioretti noted that several factors can strongly affect the development of breast cancer. If women are to be accurately stratified by risk, these factors should be considered, she said.

One of them is age. The biostatistics professor explained how age can influence the risk of breast cancer (the vast majority of breast cancers occur in women older than age 50, according to the breast cancer surveillance consortium, abbreviated as BCSC) — and what it means for screening with FFDM (full-field digital mammography) and DBT (digital breast mammography).

 

How Individual Women Can Calculate Risk

Much of the risk of developing breast cancer depends on multiple factors, which is why BCSC has come up with a breast cancer risk calculator. Miglioretti highlighted this calculator in her symposium presentation. The free-of-charge calculator is available on the web or as an iPhone-compatible app that can be downloaded. It calculates and compares a woman’s risk of cancer to that of the average woman.

“So if a woman has twice the average risk, she might consider more aggressive screening or start screening early,” Miglioretti said.

The calculator considers a woman’s:

  • Age (the risk of developing breast cancer increases with advancing age, according to the BCSC);
  • race and ethnicity (calibrated by BCSC for non-Hispanic white, non-Hispanic black, Asian/Native Hawaiian/Pacific Islander, Native American/Native Alaskan, and Hispanic women);
  • family history of breast cancer, marked by first-degree relatives — such as mother, sisters and daughters — who have had breast cancer;
  • history of breast biopsy (BCSC noted that risk especially increases if past biopsy specimens showed atypical ductal hyperplasia, a noncancerous condition in which the number of ductal cells increases or these cells look abnormal, or lobular carcinoma in situ, a noninvasive condition characterized by abnormal cells in breast lobules); and
  • breast density, which is determined by the relative amounts of fat, epithelial, and connective tissues that appear differently on mammograms due to X-ray attenuation, according to BCSC.

 

Why Considering Multiple Factors Makes Sense

Miglioretti noted that risk assessment is critically important to coming up with a personalized approach to screening, which she strongly advocates. The biggest benefit from breast cancer screening is early detection, she said, because when breast cancer is detected early, “you have more of a chance to prevent death and morbidity.“

But the chance of physical and psychological harm from screening should be considered. Either or both may result from false-positives, she said, noting that physical harm may come from unneeded chemotherapy or surgery. Psychological harm may occur when a woman thinks she has cancer but doesn’t, Miglioretti said.

The development of a personalized screening approach contrasts sharply with current guidelines, which rely heavily on a single factor, age. At least one guideline recommends that screening begin at age 50; others advise the start of screening much younger — one as early as age 40 (the American Cancer Society Guidelines for the Early Detection of Cancer.)

“But there are women in their 50s who are at lower risk than someone in their 40s,” she said. “Using a risk-based approach would actually identify more women with potential benefit from screening than using just age.”

Current guidelines may seem inconsistent because they recommend that screening start at different ages, Miglioretti said. But all guidelines say that women in their 40s should use personal choice to decide whether screening is right for them, she said: “We should empower women to make these decisions for themselves.”

Women, Miglioretti emphasized, should be encouraged to make their own choices about when to start screening and how aggressively to do so (whether annually or biannually, for example). Their decisions should be based on how they value the benefits versus harms, although some patients, she noted, may want to defer to their physicians.

“And that is fine as well,” she said. “Either way, it is the patient’s choice.”

 

Greg Freiherr is a contributing editor to Imaging Technology News (ITN). Over the past three decades, he has served as business and technology editor for publications in medical imaging, as well as consulted for vendors, professional organizations, academia, and financial institutions.

Related content:

VIDEO: Age, Interval and Other Considerations for Breast Screening

BOOK: Breast Cancer Screening: Making Sense of Complex and Evolving Evidence

 Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography

Risk Stratification for Screening Mammography: Benefits and Harms

VIDEO: A Discussion on Proposed FDA Rules for Mammography Reporting

FDA Proposes New Rules for Mammography Reporting and Quality Improvement

Related Content

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

News | Breast Imaging | July 09, 2020
July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metast
Hologic, Inc. announced he U.S. launch of the SuperSonic MACH 40 ultrasound system, expanding the company’s suite of ultrasound technologies with its first premium, cart-based system.
News | Breast Imaging | July 08, 2020
July 8, 2020 — Hologic, Inc. announced he U.S.
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing
News | Mammography | June 09, 2020
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United State
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur